Braveheart Bio, Inc. (BRVE)
| Market Cap | 1.67B |
| Revenue (ttm) | n/a |
| Net Income | -65.83M |
| EPS | -3.58 |
| Shares Out | 82.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 866,495 |
| Open | 19.29 |
| Previous Close | 19.27 |
| Day's Range | 18.83 - 21.16 |
| 52-Week Range | 16.70 - 32.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 45.50 (+123.15%) |
| Earnings Date | Nov 10, 2026 |
About BRVE
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BRVE stock is "Strong Buy." The 12-month stock price target is $45.5, which is an increase of 123.15% from the latest price.
News
Braveheart Bio Transcript: Jefferies Global Healthcare Conference
BHB-1893’s program spans Phase III trials in obstructive and non-obstructive HCM, with key data expected in 2027 and a potential obstructive filing by end-2027 or early 2028. Phase II findings include deep gradient relief, improved exercise capacity and diastolic measures, alongside simpler dosing.
Braveheart Bio price target raised to $49 from $48 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Braveheart Bio (BRVE) to $49 from $48 and keeps a Buy rating on the shares. The company’s Q3 largely recapped last week’s…
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LI...
Braveheart Bio Earnings release: Q3 2026
Braveheart Bio released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Braveheart Bio Quarterly report: Q3 2026
Braveheart Bio has published its Q3 2026 quarterly earnings report on November 10, 2026.
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart Bio Transcript: Investor update
The 52-week oHCM extension showed early gradient responses and sustained improvements in exercise capacity, symptoms and disease markers, with encouraging safety. Phase III programs span both HCM forms; fixed-dose TRUEHEART-HCM is planned to start in H1 2027.
Braveheart Bio Slides: Investor update
Braveheart Bio has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2026.
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks
Braveheart Bio management to meet with Cantor
Meeting to be held in Chicago on November 6 hosted by Cantor.
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart Bio Transcript: Stifel 2026 Virtual Cardiometabolic Forum
The forum highlighted strong clinical progress in HCM, with BHB-1893 showing rapid, deep efficacy and a differentiated safety profile. Simplified dosing, positive regulatory feedback, and robust financials position the program for global phase III advancement and potential early filing.
Braveheart Bio falls -13.9%
Braveheart Bio (BRVE) is down -13.9%, or -$4.06 to $25.14.
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopath...
Braveheart Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Lead asset BHB-1893 has shown promising phase II results in both obstructive and non-obstructive HCM, with significant biomarker and structural improvements. Global phase III trials are underway, aiming for simplified dosing and broader market adoption, supported by a robust regulatory and financial strategy.
Braveheart Bio Slides: Corporate presentation
Braveheart Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effe...
Braveheart Bio Earnings release: Q2 2026
Braveheart Bio released its Q2 2026 earnings on September 8, 2026, summarizing the period's financial results.
Braveheart Bio Quarterly report: Q2 2026
Braveheart Bio has published its Q2 2026 quarterly earnings report on September 8, 2026.
Braveheart Bio to Participate in Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopath...
Cantor starts Braveheart at Overweight on favorable setup into data
Cantor Fitzgerald initiated coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target The firm sees “plenty to play for from here” despite the stock’s recent rally.
Braveheart Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders initiated coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target
Braveheart Bio initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Braveheart Bio (BRVE) with a Buy rating and no price target The company’s BHB-1893 has generated one of the most differentiated cardiac myosin inhibitor datasets…
Braveheart Bio initiated with a Buy at Jefferies
Jefferies initiated coverage of Braveheart Bio (BRVE) with a Buy rating and $48 price target The two Phase II datasets from the company’s China partner Hengrui suggest BHB-1893 could be…